These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 17371720)

  • 21. 3D dynamic contrast-enhanced MRI of rectal carcinoma at 3T: correlation with microvascular density and vascular endothelial growth factor markers of tumor angiogenesis.
    Zhang XM; Yu D; Zhang HL; Dai Y; Bi D; Liu Z; Prince MR; Li C
    J Magn Reson Imaging; 2008 Jun; 27(6):1309-16. PubMed ID: 18504761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.
    Dafni H; Israely T; Bhujwalla ZM; Benjamin LE; Neeman M
    Cancer Res; 2002 Nov; 62(22):6731-9. PubMed ID: 12438274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology.
    Drees R; Hünigen H; Wagner S; Schnorr J; Plendl J; Taupitz M
    Vet Comp Oncol; 2008 Sep; 6(3):151-61. PubMed ID: 19178675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.
    de Lussanet QG; Beets-Tan RG; Backes WH; van der Schaft DW; van Engelshoven JM; Mayo KH; Griffioen AW
    Eur J Cancer; 2004 May; 40(8):1262-8. PubMed ID: 15110892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
    Huuse EM; Moestue SA; Lindholm EM; Bathen TF; Nalwoga H; Krüger K; Bofin A; Maelandsmo GM; Akslen LA; Engebraaten O; Gribbestad IS
    J Magn Reson Imaging; 2012 May; 35(5):1098-107. PubMed ID: 22170753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
    J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.
    Nielsen T; Murata R; Maxwell RJ; Stødkilde-Jørgensen H; Ostergaard L; Horsman MR
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):859-66. PubMed ID: 18164835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI.
    Su MY; Baik HM; Yu HJ; Chen JH; Mehta RS; Nalcioglu O
    Technol Cancer Res Treat; 2006 Aug; 5(4):401-10. PubMed ID: 16866570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of early docetaxel response in an experimental model of human breast cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H MRS.
    Jensen LR; Huuse EM; Bathen TF; Goa PE; Bofin AM; Pedersen TB; Lundgren S; Gribbestad IS
    NMR Biomed; 2010 Jan; 23(1):56-65. PubMed ID: 19650073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates.
    Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC
    Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of hypoxia in human cervical carcinoma xenografts by dynamic contrast-enhanced magnetic resonance imaging.
    Ellingsen C; Egeland TA; Gulliksrud K; Gaustad JV; Mathiesen B; Rofstad EK
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):838-45. PubMed ID: 19215820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parametric imaging of tumor perfusion using flow- and permeability-limited tracers.
    Bogin L; Margalit R; Mispelter J; Degani H
    J Magn Reson Imaging; 2002 Sep; 16(3):289-99. PubMed ID: 12205585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study.
    Chou CP; Wu MT; Chang HT; Lo YS; Pan HB; Degani H; Furman-Haran E
    Acad Radiol; 2007 May; 14(5):561-73. PubMed ID: 17434070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis.
    Bäuerle T; Bartling S; Berger M; Schmitt-Gräff A; Hilbig H; Kauczor HU; Delorme S; Kiessling F
    Eur J Radiol; 2010 Feb; 73(2):280-7. PubMed ID: 19070445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Moasser MM; Wilmes LJ; Wong CH; Aliu S; Li KL; Wang D; Hom YK; Hann B; Hylton NM
    J Magn Reson Imaging; 2007 Dec; 26(6):1618-25. PubMed ID: 17968965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macromolecular dynamic contrast-enhanced (DCE)-MRI detects reduced vascular permeability in a prostate cancer bone metastasis model following anti-platelet-derived growth factor receptor (PDGFR) therapy, indicating a drop in vascular endothelial growth factor receptor (VEGFR) activation.
    Dafni H; Kim SJ; Bankson JA; Sankaranarayanapillai M; Ronen SM
    Magn Reson Med; 2008 Oct; 60(4):822-33. PubMed ID: 18816866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A method for pharmacokinetic modelling of dynamic contrast enhanced MRI studies of rapidly enhancing lesions acquired in a clinical setting.
    Radjenovic A; Ridgway JP; Smith MA
    Phys Med Biol; 2006 May; 51(9):N187-97. PubMed ID: 16625029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.
    Choyke PL; Dwyer AJ; Knopp MV
    J Magn Reson Imaging; 2003 May; 17(5):509-20. PubMed ID: 12720260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.